$VIR News
Last published 2d ago
- 2d agoVIRECLIPSE 1 Pivotal Phase 3 Topline Results and SOLSTICE Phase 2 Finite Treatment Data - VIR BIOTECHNOLOGY INCEarnings Call TranscriptsHello, and welcome to Veer Biotechnology's Eclipse One Pivotal Phase Three Topline Results and Solstice Finite Treatment Conference Call. As a reminder, this call is being recorded. At this time, all participants are in
- 3d agoVIRVir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment DataBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). These data include new analyses presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) The Liver Meet ...
- 3d agoVIRVir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis DeltaBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). Topline results were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Live ...
- 1w agoVIRVir Biotechnology Corporate Update and Third Quarter 2026 Financial Results - VIR BIOTECHNOLOGY INCEarnings Call TranscriptsHello, and welcome to Veer Biotechnology's third quarter 2026 Financial Results and Corporate Update Conference call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode.
- 1w agoVIRVir Biotechnology, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoVIRVir Biotechnology Announces Appointment of Suzanne Topalian to its Board of DirectorsBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer
- 3w agoVIRVir Biotechnology to Host Conference Call for Third Quarter 2026 Financial ResultsBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the
- 4w agoVIRVir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid TumorsBusiness Wire- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization
- 1mo agoVIRVir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate CancerBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the
- 1mo agoVIRVir Biotechnology Appoints David Liu as Chief Medical OfficerBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for
- 1mo agoVIRVir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026Business WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming
- 1mo agoVIRVir Biotechnology Appoints Aziz Sawaf as Chief Financial OfficerBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr. Sawaf will be
- 2mo agoVIRVir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global
- 3mo agoVIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsBusiness Wire- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment - Topline
- 3mo agoVIRVir Biotechnology Announces Chief Financial Officer TransitionBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is
- 3mo agoVIRVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial ResultsBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the
- 5mo agoVIRVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. "We are pleased to welcome Tim to Vir
- 5mo agoVIRVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026Business Wire- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48 subgroup analysis from the
- 6mo agoGTBPONCYSNSEVIR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobeNewswireIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly
- 6mo agoVIR2026 GLOBAL HEALTHCARE CONFERENCEVIR BIOTECHNOLOGY INCEarnings Call TranscriptsThank you for joining this session with Veer Biotechnology. My name is Alex Stranahan. I cover Smidcap Biotech at Bank of America, and I'm the covering analyst for Veer. And it's my pleasure to introduce Marianne DeBacke
- 6mo agoVIRVir Biotechnology First Quarter 2026 Corporate Update and Financial Results Conference CallVIR BIOTECHNOLOGY INCEarnings Call TranscriptsHello, and welcome to Veer Biotechnology's First Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode.
- 6mo agoVIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial ResultsBusiness Wire- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with
- 6mo agoVIRVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference
- 6mo agoVIRVir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first
- 6mo agoVIRVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate CancerBusiness Wire- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining
- 7mo agoVIRVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate CancerBusiness WirePhase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive
- 8mo agoONCYVIRIOVACCCC+1Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesPR NewswireEquity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress ...
- 8mo agoVIRVir Biotechnology to Participate in Upcoming Investor ConferencesBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference:
- 8mo agoVIRVir Biotechnology Announces Pricing of Public Offering of Common StockBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and
- 8mo agoVIRVir Biotechnology Announces Proposed Public Offering of Common StockBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and
- 8mo agoKBLBLRMRMETAVIRBiotech and Big Tech Drive the Morning NarrativeGlobeNewswireDENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to
- 8mo agoVIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer – Reports updated VIR-5500 Phase 1
- 8mo agoVIRVir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate CancerBusiness Wire– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date – Dose-dependent anti-tumor activity was
- 8mo agoVIRAstellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate CancerPR NewswireAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have...
- 9mo agoVIRVir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the
- 9mo agoONCYMRNAMRKVIR+1Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer BenchmarksPR NewswireEquity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless...
- 11mo agoVIRVir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development ProgramBusiness Wire– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to high-twenties percent
- 11mo agoVIRVir Biotechnology to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on
- 1y agoVIRVir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety ProfileBusiness WireSOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination well-tolerated: No grade 3
- 1y agoVIRVir Biotechnology to Participate in the Jefferies 2025 London Healthcare ConferenceBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00
- 1y agoVIRVir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis DeltaBusiness Wire– ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027 – ECLIPSE registrational program on
- 1y agoVIRVir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025Business WireVir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will
- 1y agoVIRVir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate CancerBusiness Wire– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical trial builds on
- 1y agoVIRVir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025Business Wire– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to showcase progress in
- 1y agoVIRVir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoVIRVir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness WireVir Biotechnology, Inc. (NASDAQ:VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare
- 1y agoVIRVir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoVIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsBusiness Wire– ECLIPSE registrational program in chronic hepatitis delta fully underway – First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical
- 1y agoVIRVir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis DeltaBusiness WireECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with
- 1y agoVIRVir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis DeltaBusiness WireFirst patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite bulevirtide